fbpx

The Digest

Pharma news roundup and Larvol updates

Contact Us

The Digest features recent news that Larvol Pulse™ subscribers receive as well as the latest from the Larvol Team. Use the categories on the left for news in your therapeutic area of interest.

Weekly Top News – Psoriasis – November 4, 2019

November 4, 2019

Cosentyx (secukinumab) / Novartis; Humira (adalimumab) / Eisai, AbbVie
Novartis Cosentyx shows encouraging results versus Humira from first of its kind head-to-head trial in psoriatic arthritis (Novartis Press Release) – Nov 1, 2019 – P3, N=850; EXCEED (NCT02745080); Sponsor: Novartis Pharmaceuticals; “Novartis…announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira…in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira…Statistically significant advantages of Cosentyx versus Humira®* in PsA-specific endpoints were observed in a pre-specified sensitivity analysis. The trial demonstrated a consistent and favorable safety profile for Cosentyx in line with previous clinical trials…No new safety signals were detected.”

 

Taltz (ixekizumab) / Eli Lilly
Lilly presents positive results for Taltz (ixekizumab) in pediatric patients with moderate to severe plaque psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire) – Oct 28, 2019 – P3, N=201; “Eli Lilly and Company announced that TALTZ met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis…Results of the study were presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.”

 

Humira (adalimumab) / Eisai, AbbVie; Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie to showcase depth of immunology portfolio and pipeline at the 2019 ACR/ARP Annual Meeting (PRNewswire) – Nov 4, 2019 – “AbbVie…today announced it will present data from multiple studies of RINVOQ™ (upadacitinib), HUMIRA® (adalimumab) and SKYRIZI™ (risankizumab) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, November 8-13, in Atlanta. A total of 38 abstracts will be presented across multiple rheumatic conditions, including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie’s new psoriasis drug likely to win nod this year (Korea Biomedical Review) – Oct 30, 2019 – “AbbVie’s new psoriasis treatment Risankizumab is likely to obtain local license within this year, heating the competition in the psoriasis treatment market….The Ministry of Food and Drug Safety is reviewing the drug for approval, sources said.”

 

Stelara (ustekinumab) / J&J; Remicade (infliximab) / Mitsubishi Tanabe, J&J; Tremfya (guselkumab) / J&J; Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Janssen presenting data from its expanding rheumatology portfolio at the 2019 annual meeting of The American College of Rheumatology (PRNewswire) – Oct 31, 2019 – “The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will be presenting results from 30 abstracts across the company’s expanding rheumatology portfolio and pipeline products during the 2019 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting taking place in Atlanta, Georgia from November 8-13.”

 

Stelara (ustekinumab) / J&J
Stelara patent expiry: July 2024 in EU (Kepler Cheuvreux) – Oct 31, 2019 – A subscription to Thomson ONE is required to gain full access to report 68195721; Page no: 1; REPORT TITLE: “Formycon AG Espresso Note | Formycon | Buy | start of phase I for FYB202”; AUTHOR: Choplain, Damien, et al; DATE: 10/28/2019

 

Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
Ahead of World Psoriasis Day, Bausch Health, Canada announces that Siliq (brodalumab) is now covered on most drug benefit formularies in Canada (Yahoo Finance) – Oct 29, 2019 – “In advance of World Psoriasis Day on October 29, 2019 , Bausch Health Companies…is pleased to announce that SILIQ (brodalumab)3 is now listed on the majority of provincial drug benefit formularies in Canada , ensuring improved treatment access for the nearly 800,000 Canadians currently living with plaque psoriasis.”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi US sales projection: $142M in Q4 2019 and $268M in FY2019 (UBS) – Oct 29, 2019 – A subscription to Thomson ONE is required to gain full access to report 68132444; Page no: 1; REPORT TITLE: “US Pharmaceuticals “Drug launches – weekly tracker” Jacob”; AUTHOR: Jacob, Navin, et al; DATE: 10/18/2019

Read More …

Weekly Top News – Breast Cancer – October 28, 2019

October 28, 2019

Tecentriq (atezolizumab) / Roche
Tecentriq: Regulatory submissions in Japan for ovarian cancer, muscle-invasive urothelial cancer (adjuvant) and hepatocellular cancer in 2020 (Chugai) – Oct 25, 2019 – Q3 2019 Results: Regulatory submissions in Japan for early breast cancer and NSCLC (neoadjuvant) in 2021 
[Screenshot]

 

Imfinzi (durvalumab) / AstraZeneca, Celgene
Imfinzi: P2 data from P1/2 BEGONIA trial (NCT03742102) for 1L metastatic TNBC in H2 2020 (AstraZeneca) – Oct 24, 2019 – Q3 2019 Results: Data from P1/2 STUDY 1108 (NCT01693562) in advanced solid tumors in H2 2019 
[Screenshot]

 

Piqray (alpelisib) / Novartis
Piqray: CHMP opinion in EU for breast cancer in H1 2020 (Novartis) – Oct 22, 2019 – Q3 2019 Results 
[Screenshot]

 

[fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo, AstraZeneca
DS-8201: Data from P3 DESTINY-Breast02 trial (NCT03523585) for pre-treated HER2 breast cancer in 2021 (AstraZeneca) – Oct 24, 2019 – Q3 2019 Results: Data from P3 DESTINY-Breast03 trial (NCT03529110) for HER2-positive, unresectable and/or metastatic breast cancer in 2021 
[Screenshot]

 

[fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo, AstraZeneca
DS-8201: Data from P3 DESTINY-Breast04 trial (NCT03734029) for HER2-low, unresectable and/or metastatic breast cancer in 2021 (AstraZeneca) – Oct 24, 2019 – Q3 2019 Results: Data from P2 DESTINY-Gastric01 trial (NCT03329690) for HER2-overexpressing advanced gastric cancer in H1 2020 
[Screenshot]

 

Kisqali (ribociclib) / Novartis
Kisqali: Regulatory submission for HR+, HER2(-) breast cancer (adjuvant) in 2023 or later (Novartis) – Oct 22, 2019 – Q3 2019 Results 
[Screenshot]

 

[fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo, AstraZeneca
DS-8201: Acceptance of regulatory submission for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial) in 2021 (AstraZeneca) – Oct 24, 2019 – Q3 2019 Results: Acceptance of regulatory submission for HER2-positive/negative unresectable and/or metastatic breast cancer (based on DESTINY-Breast03, DESTINY-Breast04 trial) in 2021 or later 
[Screenshot]

 

margetuximab (MGAH 22) / MacroGenics
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer (GlobeNewswire, MacroGenics, Inc.) – Oct 22, 2019 – P3, N=624; SOPHIA (NCT02492711); Sponsor: MacroGenics; “Among the approximately 85% of patients carrying a CD16A 158F allele, the median OS was prolonged by 4.3 months in the margetuximab arm compared to the trastuzumab arm (23.7 months versus 19.4 months; HR=0.793; 95% CI: 0.607-1.035; p=0.087). Among the approximately 15% of patients who were homozygous for the CD16A 158V allele, the trastuzumab arm performed better than the margetuximab arm. The final pre-specified OS analysis is planned after 385 events have accrued, which is projected to occur in 2020. The first sequential primary endpoint of progression-free survival (PFS) in the ITT population was achieved, with statistical significance as previously reported.”

 

Kisqali (ribociclib) / Novartis
Women living with metastatic breast cancer in British Columbia now have public access to Kisqali (Canada Newswire) – Oct 23, 2019 – “Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that British Columbia will now reimburse KISQALI® (ribociclib) for eligible patients in combination with an aromatase inhibitor (letrozole) under its provincial public drug program (complete British Columbia reimbursement criteria can be accessed here). For women living with metastatic breast cancer, also known as Stage IV breast cancer, the cancer has spread beyond the breast to other areas of the body, such as the lungs, liver, bones or brain.”

 

Herzuma (trastuzumab biosimilar) / Nippon Kayaku, Pfizer, Mundipharma, Celltrion, Teva
Celltrion launches Herzuma in Brazil (Korea Biomedical Review) – Oct 25, 2019 – “Celltrion Healthcare said that it has launched its anticancer antibody biosimilar Herzuma in Brazil…Brazil is a primary pharmaceutical market for the trastuzumab medicine worth about 270 billion won ($230 million)….company is preparing for direct sales of Herzuma, also in Colombia, Mexico, Chile, and Peru.”

Read More …

Weekly Top News – IBD – October 28, 2019

October 28, 2019

Stelara (ustekinumab) / J&J
Janssen announces U.S. FDA approval of Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis (PRNewswire) – Oct 21, 2019 – “The Janssen Pharmaceutical Companies…announced today the U.S. Food and Drug Administration’s (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis. The approval for this new indication is based on the pivotal Phase 3 UNIFI clinical trial which achieved its primary endpoint of clinical remission.”

 

filgotinib (GLPG0634) / Gilead
Filgotinib: Data from P2b/3 SELECTION1 trial (NCT02914522) for ulcerative colitis in Q2 2020 (Gilead) – Oct 25, 2019 – Q3 2019 Results 
[Screenshot]

 

etrasimod (APD334) / Arena
Etrasimod clinical trial estimate: Initiation of P2b/3 CULTIVATE trial for Crohn’s disease in Q4 2019 (Cantor Fitzgerald) – Oct 21, 2019 – A subscription to Thomson ONE is required to gain full access to report 68024735; Page no: 3; REPORT TITLE: “Companies, catalysts and controversies: Top questions for management at our upcoming global healthcare conference”; AUTHOR: Research Department; DATE: 09/29/2019

 

Stelara (ustekinumab) / J&J
Stelara (ustekinumab) data demonstrate long-term efficacy and safety results in adults with moderately to severely active ulcerative colitis in phase 3 extension trial (Businesswire) – Oct 21, 2019 – P3, N=399; UNIFI (NCT02407236); Sponsor: Janssen Research & Development, LLC; “The Janssen Pharmaceutical Companies…announced new two-year data from the long-term extension of the Phase 3 UNIFI study, demonstrating the efficacy and safety of ustekinumab through two years of treatment in adults with moderately to severely active ulcerative colitis (UC). These data are being presented today as a late-breaking data presentation (LB01) at the 27th UEGW congress…Results showed that the majority of patients were able to sustain remission through to week 92 as assessed by symptomatic remission…Results from the UNITI Crohn’s disease (CD) clinical trial programme are also being presented at the congress.”

 

etrasimod (APD334) / Arena
Arena Pharmaceuticals presented new data analyses demonstrating the long-term safety and efficacy of once-daily etrasimod in patients with moderately to severely active ulcerative colitis at UEG Week (PRNewswire) – Oct 22, 2019 – P2, N=156; OASIS (NCT02447302); Sponsor: Arena Pharmaceuticals; “Arena Pharmaceuticals, Inc…resented new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod…in patients with moderately to severely active ulcerative colitis (UC) at the 25th Annual United European Gastroenterology (UEG) Week…’We are delighted to see that most patients who achieved clinical response, clinical remission, or endoscopic improvement at week 12 experienced sustained or improved effects up to week 46….Etrasimod also demonstrated a favorable safety profile, consistent with safety findings reported in the double-blind portion of OASIS,'”

 

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn’s disease in Feb 2022 (Eli Lilly) – Oct 23, 2019 – Q3 2019 Results: Completion of P3 VIVID-1 trial for Crohn’s disease in Jul 2023; Completion of P3 OASIS-1 trial (NCT03482011) in moderate-to-severe plaque psoriasis in Feb 2020 
[Screenshot]

 

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab: Primary completion of P3 LUCENT 1 trial (NCT03518086) in moderate-to-severe ulcerative colitis in Sep 2020 (Eli Lilly) – Oct 23, 2019 – Q3 2019 Results: Completion of P3 LUCENT 1 trial in moderate-to-severe ulcerative colitis in Dec 2021; Primary completion and completion of P2 SHINE 1 trial (NCT04004611) in children and teenagers with ulcerative colitis in Aug 2022 
[Screenshot]

 

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab: Primary completion of P3 LUCENT 2 trial (NCT03524092) in moderate-to-severe ulcerative colitis in Jun 2021 (Eli Lilly) – Oct 23, 2019 – Q3 2019 Results: Completion of P3 LUCENT 2 trial in moderate-to-severe ulcerative colitis in Jun 2023; Primary completion and completion of P3 LUCENT 3 trial (NCT03519945) in moderate-to-severe ulcerative colitis in Aug 2023 
[Screenshot]

 

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RedHill Biopharma to present new phase 3 data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting (GlobeNewswire) – Oct 28, 2019 – “RedHill Biopharma Ltd…announced that two oral presentations and two posters on two of the Company’s leading drug candidates, RHB-1051 (Talicia®, H. pylori infection) and RHB-104 (Crohn’s disease) will be presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting, being held October 25-30, in San Antonio, Texas.”

 

etrasimod (APD334) / Arena
Etrasimod US sales projection: $665M peak for ulcerative colitis (Cantor Fitzgerald) – Oct 21, 2019 – A subscription to Thomson ONE is required to gain full access to report 68047432; Page no: 2; REPORT TITLE: “Arena Pharmaceuticals Inc – Management dinner takeaways”; AUTHOR: Research Department; DATE: 10/03/2019

Read More …

Weekly Top News – Psoriasis – October 28, 2019

October 28, 2019

Tremfya (guselkumab) / J&J
Janssen brings to Spain Tremfya One-Press for the treatment of psoriasis [Google Translation] (Redacción Médica) – Oct 22, 2019 – “Janssen Pharmaceutical Companies of Johnson & Johnson has announced the commercialization in Spain of the Tremfya One-Press pre-filled pen, a new self-injectable administration device for guselkumab, indicated for the treatment of moderate to severe plaque psoriasis in adult candidates for systemic treatment….Designed to facilitate the time of the self-injection of patients with psoriasis.”

 

Tremfya (guselkumab) / J&J
Janssen seeks to expand use of Tremfya (guselkumab) in the treatment of adults with active psoriatic arthritis (Businesswire) – Oct 23, 2019 – “The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking first-in-class approval of TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA).”

 

Cosentyx (secukinumab) / Novartis
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US (GlobeNewswire) – Oct 22, 2019 – “Continuing operations net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions…Cosentyx met primary endpoints in nr-axSpA…FDA submission planned for Q4.”

 

Taltz (ixekizumab) / Eli Lilly
Lilly presents positive results for Taltz (ixekizumab) in pediatric patients with moderate to severe plaque psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire) – Oct 28, 2019 – P3, N=201; “Eli Lilly and Company announced that TALTZ met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis…Results of the study were presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.”

 

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn’s disease in Feb 2022 (Eli Lilly) – Oct 23, 2019 – Q3 2019 Results: Completion of P3 VIVID-1 trial for Crohn’s disease in Jul 2023; Completion of P3 OASIS-1 trial (NCT03482011) in moderate-to-severe plaque psoriasis in Feb 2020 
[Screenshot]

 

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab: Primary completion of P3 OASIS-2 trial (NCT03535194) in moderate-to-severe plaque psoriasis in Mar 2020 (Eli Lilly) – Oct 23, 2019 – Q3 2019 Results: Completion of P3 OASIS-2 trial in moderate-to-severe plaque psoriasis in Dec 2020; Primary completion and completion of P3 OASIS-3 trial (NCT03556202) in moderate-to-severe plaque psoriasis in May 2024 
[Screenshot]

 

GSK2831781 / GSK
GSK2831781 clinical trial estimate: Primary completion of P1 trial for healthy volunteers in Japan in January 2020 (GlobalData) – Oct 21, 2019 – A subscription to Thomson ONE is required to gain full access to report 67598395; Page no: 176; REPORT TITLE: “Immutep Ltd (IMM) – Financial analysis review”; AUTHOR: Globaldata; DATE: 09/24/2019

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Completion of P3b trial (NCT03504852) for psoriasis in H2 2020 (Novartis) – Oct 22, 2019 – Q3 2019 Results: Completion of P3 MATURE trial (NCT03589885) for psoriasis in H2 2020 
[Screenshot]

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Completion of P3 trial (NCT02471144) for psoriasis in 2023 (Novartis) – Oct 22, 2019 – Q3 2019 Results: Completion of P3 trial (NCT03668613) for psoriasis in 2023 
[Screenshot]

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Completion of P3 trial (NCT03031782) for psoriatic arthritis in 2021 (Novartis) – Oct 22, 2019 – Q3 2019 Results 
[Screenshot]

Read More …

Weekly Top News – Breast Cancer – October 21, 2019

October 21, 2019

[fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo, AstraZeneca
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer (AstraZeneca Press Release) – Oct 16, 2019 – “AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast cancer, is set for the second quarter of 2020.”

 

Lynparza (olaparib) / Merck (MSD), AstraZeneca; Keytruda (pembrolizumab) / Merck (MSD)
Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast Cancer Olaparib plusz pembrolizumab posztindukciós terápiaként tripla negatív emlőrákban (clinicaltrialsregister.eu) – Oct 17, 2019 – P2/3; N=317; Ongoing; Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc

 

Tecentriq (atezolizumab) / Roche
Tecentriq: Regulatory submissions in US/EU for neoadjuvant HER2+ breast cancer in 2022 or later (Roche) – Oct 16, 2019 – Q3 2019 Results: Regulatory submissions in US/EU in combination with capecitabine or carboplatin/gemicitabine for TNBC in 2022 or later 
[Screenshot]

 

Piqray (alpelisib) / Novartis
Piqray: Regulatory approval in EU for HR+/HER2- advanced breast cancer in 2020 (Novartis) – Oct 14, 2019 – Kisqali MONALEESA-3 ESMO Data Investor Call 
[Screenshot]

 

Kisqali (ribociclib) / Novartis
Kisqali: “The P value of 0.00455 crossed the prespecified boundary to claim superior efficacy (P < 0.01129)”; Advanced breast cancer (Novartis) – Oct 14, 2019 – Kisqali MONALEESA-3 ESMO Data Investor Call 
[Screenshot]

 

Zejula (niraparib) / GSK, J&J, Takeda
Clovis’ Rubraca approved for Cancer Drugs Fund (PharmaTimes) – Oct 14, 2019 – “NICE has also recently recommended niraparib as a treatment for this patient group and olaparib tablets for the BRCA-positive subgroup, both for use in the CDF.”

 

Keytruda (pembrolizumab) / Merck (MSD)
Keytruda regulatory estimate: Approval for TNBC in 2020 (J.P. Morgan) – Oct 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 68079155; Page no: 5; REPORT TITLE: “Merck & Co., Inc.: Does Keytruda concentration cap MRK’s multiple? We see shares as cheap on sotp basis”; AUTHOR: Schott, Christopher, et al; DATE: 10/10/2019

 

Perjeta (pertuzumab) / Roche; Tecentriq (atezolizumab) / Roche; Rozlytrek (entrectinib) / Roche
Roche reports very strong sales growth in the first nine months of 2019 – outlook raised (GlobeNewswire) – Oct 16, 2019 – “Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta…New treatment options and diagnostic test approved in the third quarter….in the US Rozlytrek for lung cancer with a specific gene mutation and solid tumours carrying a certain gene fusion; in the EU three new indications for Tecentriq: for a certain type of breast cancer; for the initial treatment of non-small cell as well as small cell lung cancer”

 

Keytruda (pembrolizumab) / Merck (MSD); AE 37 / Generex
Generex Biotechnology announces merger with public vehicle for public trading of NuGenerex Immuno-Oncology (GlobeNewswire) – Oct 15, 2019 – “Generex has positioned its wholly-owned cancer subsidiary NuGenerex Immuno-Oncology to be merged with the public company, thereby completing the company’s go-public strategy to realize the value of the Ii-Key technology and AE37 immunotherapeutic vaccine program. NGIO is currently enrolling a Phase II trial to establish the recommended biologic dose for AE37 Peptide Vaccine in combination with Keytruda® (Pembrolizumab) that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer (NSABP FB-14); the trial is currently screening and enrolling patients at multiple clinical research sites.”

 

Opdivo (nivolumab) / Ono Pharma, BMS; Keytruda (pembrolizumab) / Merck (MSD)
Uruguay to request inclusion of Opdivo, Keytruda into PAHO’s Strategic Fund (GBI Health) – Oct 14, 2019 – “According to Alicia Ferreira, head of Uruguay’s National Resources Fund (FNR), the country will call for the Pan American Health Organization (PAHO) to include Bristol-Myers Squibb (BMS)’s Opdivo (nivolumab) and Merck, Sharp & Dohme (MSD)’s Keytruda (pembrolizumab) into the Strategic Fund. The petition will be made at the next meeting of member countries, to which Janssen and MSD, the main manufacturers of Opdivo and Keytruda respectively, will be invited…The drugs, which have a monthly cost of about USD 13,000, will initially be used to treat melanoma, although their coverage will later be extended to include breast cancer and other tumors.”

Read More …
« Older Entries
Next Entries »